Johnson & Johnson (NYSE:JNJ) has raised its offer to settle thousands of lawsuits alleging its baby powder caused cancer to over $8.2B, people familiar with the matter told Bloomberg, compared to ...

Johnson & Johnson has boosted to more than $8.2 billion its offer to settle thousands of lawsuits by people who say its baby powder gave them cancer, according to people familiar with the matter.

J&J has won most of the trials in ovarian cancer cases and it successfully appealed some of its initial losses, with a $2 billion verdict standing as an outlier loss for the company.

Television advertisements soliciting claims from people who say they got cancer from talc powder products dramatically increased in September, the same month that Johnson & Johnson said it would ...

The claims contributed to a drop in J&J’s sales of baby powder, prompting the company to stop selling its talc-based products in 2020. In 2022, J&J announced plans to cease sales of the product ...

J&J Begins Crucial Battle Over $10 Billion Baby Powder Settlement. By Reuters | Feb. 18, 2025. By Reuters | Feb. 18, 2025, at 6:05 a.m. ... Dividend stocks offer long-term investors unique benefits.

The third Chapter 11 bid — including a $6.5 billion settlement offer — will likely land somewhere in the Lone Star State after judges in New Jersey concluded that thousands of cancer lawsuits ...

J&J’s decision to sweeten its settlement offer would bring the total the firm has agreed to pay out – or already expended – to resolve baby powder cases to more than $13.4 billion.

A U.S. bankruptcy court judge has denied Johnson & Johnson’s settlement plan related to baby powder containing talc, providing another setback in the company’s efforts to resolve the matter.

Bankruptcy judge denies J&J settlement plan related to baby powder containing talc The Johnson & Johnson headquarters is in New Brunswick, New Jersey, on Feb. 8, 2024. (AP Photo/Ted Shaffrey, File) ...